Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKAN Akanda	$3.63 +3.1%	$4.00	$2.91 ▼ $8.75	$1.67M	1.61	172,085 shs	150,674 shs
INDP Indaptus Therapeutics	$5.40 -12.2%	$9.15	$5.40 ▼ $58.24	$7.19M	1.27	6,222 shs	23,588 shs
JBIO Jade Biosciences	$7.49 -1.7%	$8.46	$6.57 ▼ $105.00	$257.75M	1.04	99,930 shs	50,135 shs
MYNZ Mainz Biomed	$1.66 -1.8%	$1.69	$1.30 ▼ $16.04	$7.69M	0.25	113,370 shs	35,625 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKAN Akanda	+3.13%	-7.40%	+8.56%	-8.54%	-49.93%
INDP Indaptus Therapeutics	-12.20%	-15.63%	-26.03%	-44.41%	-87.72%
JBIO Jade Biosciences	-1.71%	-5.79%	+2.74%	+748,999,900.00%	+748,999,900.00%
MYNZ Mainz Biomed	-1.78%	+2.47%	+16.90%	-16.16%	-89.44%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKAN Akanda	0.7194 of 5 stars	0.0	3.0	1.5	1.7	0.6
INDP Indaptus Therapeutics	2.7537 of 5 stars	3.5	3.0	2.4	1.7	0.6
JBIO Jade Biosciences	2.2492 of 5 stars	3.5	0.0	3.2	1.7	0.0
MYNZ Mainz Biomed	2.6406 of 5 stars	3.3	3.0	1.3	0.0	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKAN Akanda	0.00	N/A	N/A	N/A
INDP Indaptus Therapeutics	3.00	Buy	$238.00	4,307.41% Upside
JBIO Jade Biosciences	3.00	Buy	$16.00	113.62% Upside
MYNZ Mainz Biomed	2.50	Moderate Buy	$14.00	743.37% Upside

Current Analyst Ratings Breakdown

Latest AKAN, JBIO, MYNZ, and INDP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	JBIO Jade Biosciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$17.00 ➝ $18.00
7/14/2025	JBIO Jade Biosciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$16.00
6/16/2025	JBIO Jade Biosciences	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$14.00

(Data available from 9/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKAN Akanda	$840K	1.99	N/A	N/A	$9.37 per share	0.39
INDP Indaptus Therapeutics	N/A	N/A	N/A	N/A	($1.51) per share	N/A
JBIO Jade Biosciences	N/A	N/A	N/A	N/A	$6.18 per share	N/A
MYNZ Mainz Biomed	$890K	8.54	N/A	N/A	$2.61 per share	0.64

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKAN Akanda	-$4.10M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
INDP Indaptus Therapeutics	-$15.02M	-$37.66	N/A	N/A	N/A	N/A	-612.59%	-243.78%	N/A
JBIO Jade Biosciences	-$69.63M	-$30.33	N/A	∞	N/A	N/A	-51.96%	-47.65%	N/A
MYNZ Mainz Biomed	-$21.65M	-$65.60	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest AKAN, JBIO, MYNZ, and INDP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/13/2025	Q2 2025	INDP Indaptus Therapeutics	-$0.36	-$9.09	-$8.73	-$9.09	N/A	N/A
8/13/2025	Q2 2025	JBIO Jade Biosciences	-$0.43	-$0.86	-$0.43	-$0.86	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKAN Akanda	N/A	N/A	N/A	N/A	N/A
INDP Indaptus Therapeutics	N/A	N/A	N/A	N/A	N/A
JBIO Jade Biosciences	N/A	N/A	N/A	N/A	N/A
MYNZ Mainz Biomed	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKAN Akanda	N/A	1.39	1.39
INDP Indaptus Therapeutics	N/A	0.75	0.75
JBIO Jade Biosciences	N/A	10.31	10.31
MYNZ Mainz Biomed	0.14	1.32	1.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKAN Akanda	1.00%
INDP Indaptus Therapeutics	7.06%
JBIO Jade Biosciences	N/A
MYNZ Mainz Biomed	N/A

Insider Ownership

Company	Insider Ownership
AKAN Akanda	20.39%
INDP Indaptus Therapeutics	20.80%
JBIO Jade Biosciences	24.90%
MYNZ Mainz Biomed	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKAN Akanda	110	460,000	364,000	Not Optionable
INDP Indaptus Therapeutics	6	1.11 million	877,000	Not Optionable
JBIO Jade Biosciences	20	32.63 million	24.50 million	N/A
MYNZ Mainz Biomed	30	4.58 million	N/A	Not Optionable

AKAN, JBIO, MYNZ, and INDP Headlines

Recent News About These Companies

Mainz Biomed Announces Registration of ColoAlert in the United Kingdom

September 2 at 8:01 AM | globenewswire.com

Mainz Biomed receives Swiss regulatory approval to market ColoAlert

August 14, 2025 | msn.com

Mainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert®

August 13, 2025 | globenewswire.com

Mainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and Warrants

August 4, 2025 | globenewswire.com

Mainz Biomed files to sell 1.47M ordinary units

July 31, 2025 | msn.com

EQS-News: Mainz Biomed and CARE Conclude Cooperation Agreement for Joint Care Concept for Health Insurance Companies

July 24, 2025 | finanzen.atF

Mainz Biomed and CARE Conclude Cooperation Agreement for Joint Care Concept for Health Insurance Companies

July 23, 2025 | globenewswire.com

Mainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening Acquisition

July 15, 2025 | globenewswire.com

Mainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening Acquisition

July 15, 2025 | globenewswire.com

Mainz Biomed BV News (MYNZ) - Investing.com

July 4, 2025 | investing.com

Mainz Biomed erhält staatliche Förderung für die Entwicklung seines innovativen Tests zur Früherkennung von Bauchspeicheldrüsenkrebs

June 25, 2025 | anlegerplus.deA

Mainz BioMed NV: Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test

June 25, 2025 | finanznachrichten.de

Mainz Biomed BV Aktie | MYNZ Kurs | Realtime - Investing.com

June 25, 2025 | de.investing.com

EQS-News: Mainz Biomed erhält staatliche Förderung für die Entwicklung seines innovativen Tests zur Früherkennung von Bauchspeicheldrüsenkrebs

June 25, 2025 | boerse.deB

Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test

June 25, 2025 | globenewswire.com

Promising Advancements in Cancer Diagnostics Propel Mainz Biomed B.V. to a Buy Rating

June 11, 2025 | tipranks.com

Mainz BioMed NV: Mainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer Project

June 10, 2025 | finanznachrichten.de

Mainz Biomed startet Machbarkeitsstudie zu Biomarker-Panel im Rahmen seines Projekts zur Behandlung von Bauchspeicheldrüsenkrebs

June 10, 2025 | anlegerplus.deA

Mainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer Project

June 10, 2025 | finance.yahoo.com

Mainz Biomed Initiates Feasibility Phase for Non-Invasive Pancreatic Cancer Screening Test in PancAlert Project

June 10, 2025 | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKAN, JBIO, MYNZ, and INDP Company Descriptions

Akanda NASDAQ:AKAN

$3.63 +0.11 (+3.13%)

Closing price 09/3/2025 04:00 PM Eastern

Extended Trading

$3.64 +0.01 (+0.28%)

As of 09/3/2025 07:49 PM Eastern

Akanda Corp., through its subsidiaries, engages in the cultivation, manufacture, and distribution of cannabis products to patients worldwide. It offers medicinal-grade cannabis and cannabis based medical and wellness products. The company was incorporated in 2021 and is headquartered in New Romney, the United Kingdom.

Indaptus Therapeutics NASDAQ:INDP

$5.40 -0.75 (-12.20%)

Closing price 09/3/2025 03:59 PM Eastern

Extended Trading

$5.70 +0.30 (+5.63%)

As of 09/3/2025 05:19 PM Eastern

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

Jade Biosciences NASDAQ:JBIO

$7.49 -0.13 (-1.71%)

As of 09/3/2025 04:00 PM Eastern

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Mainz Biomed NASDAQ:MYNZ

$1.66 -0.03 (-1.78%)

Closing price 09/3/2025 04:00 PM Eastern

Extended Trading

$1.72 +0.06 (+3.31%)

As of 09/3/2025 04:54 PM Eastern

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time